SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Interestingly, the recommendation to introduce SGLT2 inhibitors in NAFLD patients with T2DM is already included in guidelines developed by the Japanese Society of Gastroenterology in collaboration with the Japan Society of Hepatology [44].